LNTH Q4 2021 Earnings — Lantheus Holdings, Inc. Revenue & Financial Results | Market Cap Arena

LNTHLantheus Holdings, Inc.

$6B

Q4 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$130M+37.6% YoY

Gross Profit

$58M44.7% margin

Operating Income

-$35M-27.3% margin

Net Income

-$40M-31.0% margin

EPS (Diluted)

$-0.59

QoQ Revenue Growth

+26.9%

Cash Flow

Operating Cash Flow

$14M

Free Cash Flow

$9M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$864M

Total Liabilities

$399M

Stockholders' Equity

$464M

Cash & Equivalents

$99M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$130M	$94M	+37.6%
Gross Profit	$58M	$39M	+49.8%
Operating Income	-$35M	-$528,000	-6592.8%
Net Income	-$40M	-$3M	-1078.6%

Revenue Segments

Total Precision Diagnostics

$87M39%

DEFINITY

$59M27%

Radiopharmaceutical Oncology

$36M16%

Techne Lite

$22M10%

Strategic Partnerships And Other

$7M3%

License and Royalty Revenues

$7M3%

Other Precision Diagnostics

$6M3%